Slides:

Advertisements

Similar presentations

Giancarlo Agnelli Università di Perugia Anticoagulant treatment for PE: optimal duration.

Advertisements

+ Deep Vein Thrombosis Common, Preventable, and potentially Fatal.

Deep Vein Thrombosis (DVT)

 When untreated, general postsurgical patients risk for Deep Venous Thrombosis (DVT) is 19%-25% (Buckner, et al., 2013).  Post surgical orthopedic patients.

 Incidence rate (symptomatic): 1%  ½ occur after discharge  We don’t understand which patients are at highest risk.

Soff 4/15/2017 Thrombosis In Cancer: Gerald A Soff MD.

The Definitive Thrombosis Update

PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM

Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer Agnelli G et al. N Engl J Med 2012;366(7): George D et al. Proc.

Cancer-Associated Thrombosis

Surgical Care Improvement Project Prevention of Post-operative Venous Thromboembolism Team Membership Department of Surgery, Nursing, General Medicine,

Pulmonary Embolism Treatment in Cancer - Is It Different 34th Brazilian Thoracic Conference 6th ALAT Congress 5th Brazil-Portugal Congress Brazilia/DF.

EFFICACY OF ELECTRICAL MUSCLE STIMULATION IN CLINICAL PRACTICE V.N. Obolenskiy 1,2 1 City Hospital #13 (Moscow, Russia), 2 RNRMU (Moscow, Russia)

ST CATHERINE’S HOSPICE Primary thromboprophylaxis in advanced disease MJ Johnson.

Deep vein thrombosis Pulmonary embolism Deep vein thrombosis Pulmonary embolism Venous Thromboembolism TreatmentTreatment …All the same?

Surgical Care Improvement Project Prevention of Post-operative Venous Thromboembolism Team Membership Department of Surgery, Nursing, General Medicine,

Higher Incidence of Venous Thromboembolism (VTE) in the Outpatient versus Inpatient Setting Among Patients with Cancer in the United States Khorana A et.

Confidential: Quality Improvement Material Reducing Clotting Events for Post-Surgical Orthopedic Patients Loyola Anticoagulation Clinic Spring 2009.

Oral Rivaroxaban Compared with Subcutaneous Enoxaparin for Extended Thromboprophylaxis After Total Hip Arthroplasty: The RECORD1 Trial Eriksson BI, Borris.

Oral, Direct Factor Xa Inhibition with Rivaroxaban for the Prevention of Venous Thromboembolism After Total Hip Replacement Eriksson BI, Borris L, Dahl.

Fundamental Research in Oncology & Thrombosis FRONTLINE 1 Survey.

Venous Thromboembolic (VTE) Prophylaxis in Pediatric Trauma Patients Bowe.

Conclusions Results Methods Background Venous thrombo-embolism in patients undergoing neo- adjuvant chemotherapy and surgery for oesophago-gastric cancer.

Management of Deep Vein Thrombosis and Pulmonary Embolism by Jack Hirsh, and John Hoak Circulation Volume 93(12): June 15, 1996 Copyright © American.

Review on NOACs Studies DR. KOUROSH SADEGHI TEHRAN UNIVERSITY OF MEDICAL SCIENCES.

VTE prophylaxis Sharif-Kashani,B.MD SBMU Preventing VTE Over 12 million people in the United States are at risk of VTE due to hospitalization for major.

Chapter 9: Vascular Complications of Cancer and Cancer Treatment

Taylor Butler, PharmD, BCOP Decentralized Clinical Pharmacist

Postoperative Calf Venous Thrombosis: Location, Location, Location

Volume 149, Issue 5, Pages (May 2016)

Clinical Professor in Palliative Medicine

Venous Thromboembolism Prophylaxis (VTE)

Evaluating The Accuracy Of International Classification Of Diseases 10TH Revision Codes For Venous Thromboembolism (VTE) And Major Bleeding (MB) in.

The Evaluation of Suspected Pulmonary Embolism

UNDERSTANDING YOUR RISK FOR DEVELOPING BLOOD CLOTS (VTE) IN CANCER

APEX Trial design: Patients hospitalized with an acute medical illness were randomized to oral betrixaban for days (n = 3,759) versus subcutaneous.

Copyright © 2012 American Medical Association. All rights reserved.

VTE Management Issues In Malignancy

UNDERSTANDING YOUR RISK FOR DEVELOPING BLOOD CLOTS (VTE) IN CANCER

The relation between venous and arterial thrombosis

Waleed Alselwi1, Thomas Coventary2, Faisal Azam1

CREATED BY: Shannon Dembowske

The heart and science of medicine.

-LIVE Global Activities-

Antithrombotic Therapy

NOACs for Cancer-Associated Thrombosis:

Extended Treatment of VTE: Who is the Right Candidate?

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis by Paolo Prandoni,

Daniel C. Thomas, MD, MPH, Brian N. Arnold, MD, Jessica R

Timothy A. Brighton, M. B. , B. S. , John W. Eikelboom, M. B. , B. S

Venous Thromboembolism AND Cancer: Prediction and prevention

Paul D. Stein, MD, Russell D. Hull, MBBS, MSc, Fadi Matta, MD, Abdo Y

Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated With Mortality In Patients With Prostate Cancer by Shruti Chaturvedi, Surbhi.

New Oral Anticoagulants and VTE Management

Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein.

Venous Thromboembolism with Chronic Liver Disease

Influence of Renal Function on the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Non–Vitamin K Antagonist Oral Anticoagulants Matthew R.

A Systematic Review of Pulmonary Embolism in Patients With Lung Cancer

NOAC Studies in VTE AF Studies Superior Outcomes.

References: What is the connection between VTE and active cancer? 1. Khorana AA, Francis CW, Culakova E et al. Thromboembolism.

References: Oncological Surgyery: 1. ASCO: Lyman GH, Bohlke K, Khorana AA, et al. Venous Thromboembolism Prophylaxis and Treatment.

How I treat cancer-associated venous thromboembolism

Treatment and secondary prevention strategy diagram for VTE in patients with active cancer based on the treatment guidelines for cancer-associated VTE.

Incidence of (A) recurrent VTE and (B) major bleeding in select randomised clinical trials of LMWH for the treatment and secondary prevention of VTE in.

References: Anticoagulation should be continued 3-6 months for the treatment of VTE in cancer patients: 1. ASCO: Lyman GH, Bohlke K, Khorana AA, et al.

Treatment algorithm. Treatment algorithm. (A) Suggested treatment algorithm for symptomatic and incidental DVT or PE in cancer patients. (B) Suggested.

Potential protocol for the treatment of pulmonary embolism (PE), incorporating direct oral anticoagulants (OACs). Potential protocol for the treatment.

Cumulative prevalence of venous thromboembolic events in ITP patients who underwent splenectomy compared with those who did not. Cumulative prevalence.

Presentation transcript:

References: Despite the well-known association of VTE and cancer, patients are woefully unaware of that risk and of warning signs and symptoms: 1. Lyman GH, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. Journal of Clinical Oncology. 2013 May 13;31(17):2189-204. 2. Noble S, Matzdorff A, Maraveyaspatients' anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology. Haematologica 2015; 100(11): 1486-92 VTE can be detected on imaging studies conducted for other indications, typically while staging cancer: 1. Khorana A. et al, Incidental Venous Thromboembolism in Oncology Patients. JTH 2012; Dec; 10(12): 2602-4 2. O’Connell C.L, et al. Unsespected Pulmonary Emboli in Cancer Patients: Clinical Correlates and Relevance. JCO 2006; 24;4928-4932 3. Stein PD, et al. Chest 1995;110:978–81 4. Sander DA, et al. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med 1969;82:203–5. 5. Nicolaides AN, Fareed J, Kakkar AK, Breddin HK. Prevention and treatment of venous thromboembolism International Consensus Statement (guidelines according to scientific evidence). International Angiology. 2006 Jun 1;25(2):101 High rates of incidental VTE: 1. Moore RA, Adel N, Riedel E, Bhutani M, Feldman DR, Tabbara NE, Soff G, Parameswaran R, Hassoun H. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. Journal of Clinical Oncology. 2011 Aug 1;29(25):3466-73. 2. Menapace LA, Peterson DR, Berry A et al. Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer. Thromb Haemost 2011;106:371–378 Similar outcomes for cancer patients with incidental & symptomatic PE: 1. Den Exter PL, Hooijer J, Dekkers OM, Huisman MV. Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients. Journal of Clinical Oncology. 2011 May 9;29(17):2405-9.